• Filter by age range:
  • all adults (15-64) |
  • young adults (15–34) |
  • youngest adults (15–24)
• Filter by prevalence type:
  • lifetime (LTP) |
  • last month (LMP) |
  • last year (LYP)

Statistics found here the category is General population surveys of drug use (GPS)

Category	Title
GPS	GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys
GPS	GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-3. Last month prevalence of cannabis among the 15-to 24-year old age group, measured by national surveys
GPS	GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys Part (i) All countries
GPS	GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys Part (ii) Countries with three or more surveys
GPS	GPS-5. Last year prevalence of amphetamines among young adults aged 15 to 34 and 15 to 24, measured by population surveys
GPS	GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS	GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (i) All Member States with available information
GPS	GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (ii) Males 15 to 24 in Member States with higher prevalence rates
GPS	GPS-10. Last year prevalence of cannabis by age group in United Kingdom (E&W), measured by national population surveys
GPS	GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available Part (i) Last year prevalence in some of the EU-15 Member States
GPS	GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available Part (ii) Last year prevalence in some new EU Member States
GPS	GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
GPS	GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
GPS	GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34)
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use — lifetime experience, last year and last month prevalence
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last year and last month prevalence
GPS	GPS-20. Figure GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country
GPS	GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom (E&W)
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (ii) Denmark
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iii) Germany
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iv) Spain
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) France
GPS	GPS-0. Nationwide surveys among the general population: Bibliographic references
GPS	GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults
GPS	GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population Part (ii) Survey methods
GPS	GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
GPS	GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
GPS	GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (i) Frequency of use among all users in last month (percentage) — 2007 field trial
GPS	GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part (ii) Frequency of use among all users in last month (percentage) — 2004 field trial
GPS	GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population. Part (i) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population. Part (ii) Survey methods: last survey available for each Member State (from 2000 onwards)
GPS	GPS-9. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-10. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-11. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-12. Last month percentage prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-13. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-14. Lifetime prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-15. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-16. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
GPS	GPS-18. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
GPS	GPS-19. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-121. Methodological information for nation-wide surveys among the general population